[
  {
    "ts": "2026-01-22T06:03:30+00:00",
    "headline": "Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality",
    "summary": "The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a ‌drag that will likely dent revenues and raise costs for companies in the coming years, 15 investors and analysts told Reuters.",
    "url": "https://finance.yahoo.com/news/vaccine-makers-feel-chill-us-060330763.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "b058023d-98a0-30d2-9505-759b3108ff8d",
      "content": {
        "id": "b058023d-98a0-30d2-9505-759b3108ff8d",
        "contentType": "STORY",
        "title": "Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality",
        "description": "",
        "summary": "The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a ‌drag that will likely dent revenues and raise costs for companies in the coming years, 15 investors and analysts told Reuters.",
        "pubDate": "2026-01-22T06:03:30Z",
        "displayTime": "2026-01-22T06:03:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/1c54fd957ecc08ee53dfbb48ad3dd888",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EuBRqDuDSPNrtoA3GBOGSg--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1c54fd957ecc08ee53dfbb48ad3dd888.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pFdbe6h5J3wm8QCnJ9FMPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1c54fd957ecc08ee53dfbb48ad3dd888.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vaccine-makers-feel-chill-us-060330763.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vaccine-makers-feel-chill-us-060330763.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T11:50:00+00:00",
    "headline": "Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?",
    "summary": "The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.",
    "url": "https://www.fool.com/investing/2026/01/22/pfizer-absurdly-cheap-dividend-stock-or-value-trap/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "3c288dc9-a5c0-3be0-bf4e-d4cf61bb56de",
      "content": {
        "id": "3c288dc9-a5c0-3be0-bf4e-d4cf61bb56de",
        "contentType": "STORY",
        "title": "Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?",
        "description": "",
        "summary": "The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.",
        "pubDate": "2026-01-22T11:50:00Z",
        "displayTime": "2026-01-22T11:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5c1cf8fc51f6e85bdbddba4f4ecbe087",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A patient undergoing a checkup at a doctor's office.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9o8kIQHbmWQVDsmWLIpvSg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5c1cf8fc51f6e85bdbddba4f4ecbe087.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HlOGqJ3ia92u.9BQ6rcAHQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5c1cf8fc51f6e85bdbddba4f4ecbe087.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/22/pfizer-absurdly-cheap-dividend-stock-or-value-trap/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-absurdly-cheap-dividend-stock-115000237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T05:01:00+00:00",
    "headline": "Johnson & Johnson Crushes Patent, Pricing Probs",
    "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
    "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-overcomes-patent-and-pricing-probs/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "83ac5d47-79c6-3480-bb94-59e28df067fd",
      "content": {
        "id": "83ac5d47-79c6-3480-bb94-59e28df067fd",
        "contentType": "STORY",
        "title": "Johnson & Johnson Crushes Patent, Pricing Probs",
        "description": "",
        "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
        "pubDate": "2026-01-22T05:01:00Z",
        "displayTime": "2026-01-22T05:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/1e08a807ac8f7d9f274aa9b98d94e229",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of the Johnson & Johnson MedTech office building in Santa Clara, California.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nr86Y11pS4sCbCQI4._JxA--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/1e08a807ac8f7d9f274aa9b98d94e229.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vUVYM1W11zirRR8M_aQYGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/1e08a807ac8f7d9f274aa9b98d94e229.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-overcomes-patent-and-pricing-probs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-crushes-patent-pricing-050100914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T13:05:00+00:00",
    "headline": "Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "PALO ALTO, Calif., January 22, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.",
    "url": "https://finance.yahoo.com/news/guardant-health-receives-fda-approval-130500856.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "e9999c24-0ee8-3681-9408-cff444dccda2",
      "content": {
        "id": "e9999c24-0ee8-3681-9408-cff444dccda2",
        "contentType": "STORY",
        "title": "Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
        "description": "",
        "summary": "PALO ALTO, Calif., January 22, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.",
        "pubDate": "2026-01-22T13:05:00Z",
        "displayTime": "2026-01-22T13:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/873e977ad3042b364c8068e4501aabe7",
          "originalWidth": 1806,
          "originalHeight": 619,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6StyqOj2IRWsxmipk3sCIQ--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/873e977ad3042b364c8068e4501aabe7.cf.webp",
              "width": 1806,
              "height": 619,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n_vKSKi.B6wVVfMYmaH.Rg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/873e977ad3042b364c8068e4501aabe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/guardant-health-receives-fda-approval-130500856.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/guardant-health-receives-fda-approval-130500856.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T14:15:00+00:00",
    "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
    "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
    "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f5fef165-ab14-3534-b7b8-9cc6de40c73d",
      "content": {
        "id": "f5fef165-ab14-3534-b7b8-9cc6de40c73d",
        "contentType": "STORY",
        "title": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
        "description": "",
        "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
        "pubDate": "2026-01-22T14:15:00Z",
        "displayTime": "2026-01-22T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-deep-pipeline-key-next-141500295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T21:59:00+00:00",
    "headline": "Clorox to Buy Purell-Maker Gojo for $2.25 Billion",
    "summary": "Clorox said the all-cash deal, which is being funded with debt, will help it expand further into the health and hygiene categories.",
    "url": "https://www.wsj.com/business/deals/clorox-to-buy-purell-maker-gojo-for-2-25-billion-07e5d747?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "a5b149ba-5ff8-3e2e-9c6b-e1328f9e2141",
      "content": {
        "id": "a5b149ba-5ff8-3e2e-9c6b-e1328f9e2141",
        "contentType": "STORY",
        "title": "Clorox to Buy Purell-Maker Gojo for $2.25 Billion",
        "description": "",
        "summary": "Clorox said the all-cash deal, which is being funded with debt, will help it expand further into the health and hygiene categories.",
        "pubDate": "2026-01-22T21:59:00Z",
        "displayTime": "2026-01-22T21:59:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a5b149ba-5ff8-3e2e-9c6b-e1328f9e2141/clorox-to-buy-purell-maker.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/9b00ea454d866c499c76012b46b60812",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HkvTcAoodKOuJi6pFY4NJA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/9b00ea454d866c499c76012b46b60812.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CBgpfa6Ypheb5KnRuqOzYQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/9b00ea454d866c499c76012b46b60812.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/deals/clorox-to-buy-purell-maker-gojo-for-2-25-billion-07e5d747?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CLX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]